Key features and details
- Rabbit polyclonal to IRF1
- Suitable for: WB, ICC, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-IRF1 antibody
See all IRF1 primary antibodies
DescriptionRabbit polyclonal to IRF1
SpecificityNo cross reactivity with other proteins.
Tested applicationsSuitable for: WB, ICC, IHC-Pmore details
Species reactivityReacts with: Human
- COLO320, U87, HeLa, Jurkat and MCF-7 cell lysates; Human intestinal cancer tissue.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservatives: 0.025% Thimerosal (merthiolate), 0.025% Sodium azide
Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Sodium phosphate
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab191032 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.1 - 0.5 µg/ml. Predicted molecular weight: 36 kDa.|
|ICC||Use a concentration of 0.5 - 1 µg/ml.|
|IHC-P||Use a concentration of 0.5 - 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionSpecifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) and activates those genes. Acts as a tumor suppressor.
Involvement in diseaseDefects in IRF1 are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
Sequence similaritiesBelongs to the IRF family.
Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
modificationsSumoylation represses the transcriptional activity and displays enhanced resistance to protein degradation. Inactivates the tumor suppressor activity. Elevated levels in tumor cells. Major site is Lys-275. Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 in tumor cells and appears to compete with ubiquitination on C-terminal sites.
Ubiquitinated. Appears to compete with sumoylation on C-terminal sites.
- Information by UniProt
- Interferon regulatory factor 1 antibody
- Interferon regulatory factor 1 isoform +I9 antibody
- Interferon regulatory factor 1 isoform d78 antibody
All lanes : Anti-IRF1 antibody (ab191032) at 0.5 µg/ml
Lane 1 : COLO320 cell lysate
Lane 2 : U87 cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : Jurkat cell lysate
Lane 5 : MCF-7 cell lysate
Predicted band size: 36 kDa
Immunohistochemical analysis of formalin-fixed, paraffin-embedded human intestinal cancer tissue labeling IRF1 with ab191032 at 1 μg/ml.
Immunocytochemical analysis of HeLa cells labelling IRF1 with ab191032 at 1μg/ml
ab191032 has been referenced in 1 publication.
- Koelzer VH et al. Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. Oncoimmunology 6:e1288330 (2017). PubMed: 28507795